Is it necessary to continue using pemetinib for a long time after taking it?

Pemigatinib is a selective FGFR (fibroblast growth factor receptor) inhibitor mainly used to treat locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. According to the characteristics of the indication, this drug is generally used for patients after tumor progression or for patients in whom chemotherapy is ineffective. Whether long-term use is required depends on the patient's response to treatment, disease stability, and tolerability of side effects. If the drug maintains good control over a period of time and is well tolerated by the patient, doctors usually recommend continued use to prevent recurrence or progression of the disease.

In tumor treatment, pemetinib inhibits the activity of the FGFR pathway, thereby slowing down the growth and spread of cancer cells. This mechanism determines that it needs to act on tumor cells for a long time to maintain its efficacy. Clinical trials have shown that some patients can maintain a stable disease state after continuing to take the drug for several months or even more than a year. Therefore, it is usually recommended that patients continue to use the drug until serious adverse reactions occur or the disease progresses. Stopping the drug may often lead to a rebound or rapid deterioration of the disease.

The use of pemetinib may cause a rapid rebound of the disease once the drug is discontinued, especially when complete remission has not been clearly achieved. Therefore, even if the patient's symptoms are relieved in the short term, he cannot stop taking the medication without authorization. Whether to discontinue medication must undergo strict medical evaluation, including imaging examinations, tumor marker monitoring, and symptom observation. If the patient experiences severe side effects that lead to intolerance, the doctor will consider reducing the dose, intermittent use, or switching to other treatment options. However, this decision requires individual judgment and cannot be made by oneself.

Although it is recommended to continue taking the drug from a medical perspective, in reality, some patients may stop taking the drug midway due to financial burden and side effects of long-term medication (such as hyperphosphatemia, rash, eye discomfort, etc.). In this case, the doctor will evaluate whether the medication regimen can be appropriately adjusted, such as taking "intermittent medication" or combining it with other drugs to control the condition. Therefore, whether pemetinib must be used continuously for a long time requires scientific decision-making under the guidance of a doctor, comprehensively considering the condition, efficacy, safety and the patient's personal condition.

Reference materials:https://go.drugbank.com/drugs/DB15102